A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
Latest Information Update: 04 Mar 2024
At a glance
- Drugs DT-216 (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Proof of concept
- Sponsors Design Therapeutics
Most Recent Events
- 27 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Aug 2023 According to a Design Therapeutics media release, the company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and Report Data in the First Half of 2025.
- 14 Aug 2023 According to a Design Therapeutics media release, the company has elected to complete dose escalation in this Phase 1 study at the 300mg cohort due to concern for potential worsening of injection site thrombophlebitis at higher doses with multiple administration. The company to host a live webcast and conference call today at 4:30 pm ET to discuss data from this trial.